In this episode of S&C’s Critical Insights podcast, Frank Aquila, Global Head of M&A, and Matt Hurd, co-head of our Healthcare & Life Sciences group, examine industry and regulatory trends that will reshape pharmaceutical M&A in the coming years. Frank and Matt explore how innovation continues to drive new deal-making opportunities in the pharmaceutical industry, most recently in the development of non-traditional vaccine technologies. They also discuss the current deal landscape in pharmaceutical M&A and what we can expect from the market in the rest of 2021.